Ono Pharmaceutical Co. Ltd.
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 15 disclosed transactions, Ono Pharmaceutical Co. Ltd. concentrates its licensing activity in Oncology, Other, and Immunology. Ono Pharmaceutical Co. Ltd. pays a 1.03x premium over market median. Their most common deal structure is License, with an average disclosed value of $506M. Most recent activity: 2025.
Pipeline coverage & gaps
Ono Pharmaceutical Co. Ltd. has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 9 | $88M | $374M |
| Option | 5 | $17M | $363M |
| Acquisition | 1 | $2.4B | $2.4B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | sapablursen | Ionis Pharmaceuticals, Inc. | polycythemia vera | phase_2 | $280M | $940M |
| 2025 | Sapablursen (IONIS-TMPRSS6-LRx) | Ionis Pharmaceuticals | polycythemia vera | phase_2 | $280M | $940M |
| 2024 | gist | Deciphera Pharmaceuticals | gist | approved | $2.4B | $2.4B |
| 2024 | — | Shattuck Labs, Inc. | — | discovery | $5M | $230M |
| 2022 | Itolizumab | Equillium | lupus nephritis | phase_3 | $26M | $165M |
| 2022 | itolizumab | Equillium | acute graft-versus-host disease, lupus nephritis | phase_3 | $26M | $163M |
| 2020 | iPSC-derived CAR-T cell therapy (second candidate) | Fate Therapeutics, Inc. | solid_tumor | discovery | — | $10M |
| 2019 | 5F9 | Forty Seven Inc. | solid_tumor | phase_2 | $16M | $119M |
| 2019 | 5F9 | Forty Seven, Inc. | — | phase_1 | $16M | $120M |
| 2018 | iPSC-derived cell therapy platform | Fate Therapeutics, Inc. | — | preclinical | $10M | $1.3B |
| 2017 | selinexor | Karyopharm Therapeutics Inc. | solid_tumor | phase_3 | $22M | $193M |
| 2017 | binimetinib and encorafenib | Array BioPharma | BRAF-mutant advanced melanoma, BRAF-mutant colorectal cancer | phase_3 | $31M | $187M |
| 2017 | binimetinib and encorafenib | Array BioPharma Inc. | solid_tumor | phase_3 | $31M | $187M |
| 2010 | carfilzomib and oprozomib (ONX 0912) | Onyx Pharmaceuticals, Inc. | all oncology indications | phase_2 | $59M | $339M |
| 2010 | carfilzomib and oprozomib (ONX 0912) | Onyx Pharmaceuticals, Inc. | multiple myeloma | phase_2 | $59M | $344M |
How this is computed
For each Ono Pharmaceutical Co. Ltd. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 1.030, clamped to [0.7, 1.5].